Replies to post #215600 on Biotech Values

[dewophile]

The article suggests compromised immunity as one negative consequence from interfering with the complement cascade, but I am sure you got that too. The article did bring me back to this comment from GSK regarding the competitive prospects of their HIF stabilizer:

We had molecules before that inhibited collagen-4-hydroxylase. I can tell you that
you don't want to do that: that causes a cardiac problem in animals and we think that is an
important thing to completely avoid

https://www.gsk.com/media/1442/randd-day-transcript-full.pdf

Now to be clear I don't think there is a large risk here, and Peter makes a good point regarding dosing. But after a run up I personally decided to play it safe and take profits (which of course means the stock is destined to go up ;)